TISIDB: an integrated repository portal for tumor-immune system interactions
暂无分享,去创建一个
Beibei Ru | Jiangwen Zhang | Yin Tong | Ching Ngar Wong | Jia Yi Zhong | Sophia Shek Wa Zhong | Wai Chung Wu | Ka Chi Chu | Choi Yiu Wong | Chit Ying Lau | Ian Chen | Nam Wai Chan | Jiangwen Zhang | Yin Tong | Beibei Ru | I. Chen | Wai Chung Wu | J. Zhong | Chit-Ying Lau | S. Zhong | Choi Yiu Wong
[1] K. D. de Visser,et al. Cancer‐Cell‐Intrinsic Mechanisms Shaping the Tumor Immune Landscape , 2018, Immunity.
[2] D. Felsher,et al. MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.
[3] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[4] M. Vignali,et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis , 2017, PLoS medicine.
[5] Deepak Mittal,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[6] Henry W. Long,et al. A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.
[7] Mark W. Ball,et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.